» Articles » PMID: 18342009

The Ubiquitin-editing Enzyme A20 Restricts Nucleotide-binding Oligomerization Domain Containing 2-triggered Signals

Overview
Journal Immunity
Publisher Cell Press
Date 2008 Mar 18
PMID 18342009
Citations 187
Authors
Affiliations
Soon will be listed here.
Abstract

Muramyl dipeptide (MDP), a product of bacterial cell-wall peptidoglycan, activates innate immune cells by stimulating nucleotide-binding oligomerization domain containing 2 (NOD2) -dependent activation of the transcription factor NFkappaB and transcription of proinflammatory genes. A20 is a ubiquitin-modifying enzyme that restricts tumor necrosis factor (TNF) receptor and Toll-like receptor (TLR) -induced signals. We now show that MDP induces ubiquitylation of receptor- interacting protein 2 (RIP2) in primary macrophages. A20-deficient cells exhibit dramatically amplified responses to MDP, including increased RIP2 ubiquitylation, prolonged NFkappaB signaling, and increased production of proinflammatory cytokines. In addition, in vivo responses to MDP are exaggerated in A20-deficient mice and in chimeric mice bearing A20-deficient hematopoietic cells. These exaggerated responses occur independently of the TLR adaptors MyD88 and TRIF as well as TNF signals. These findings indicate that A20 directly restricts NOD2 induced signals in vitro and in vivo, and provide new insights into how these signals are physiologically restricted.

Citing Articles

Exploring the role of ubiquitination modifications in migraine headaches.

Zhu Q, Yang J, Shi L, Zhang J, Zhang P, Li J Front Immunol. 2025; 16:1534389.

PMID: 39958329 PMC: 11825825. DOI: 10.3389/fimmu.2025.1534389.


A20 as a Potential Therapeutic Target for COVID-19.

Wu Y, He L, Li R, Li J, Zhao Q, Shao B Immun Inflamm Dis. 2025; 13(1):e70127.

PMID: 39853876 PMC: 11760982. DOI: 10.1002/iid3.70127.


A20 intrinsically influences human effector T-cell survival and function by regulating both NF-κB and JNK signaling.

Dabbah-Krancher G, Ruchinskas A, Kallarakal M, Lee K, Bauman B, Epstein B Eur J Immunol. 2024; 54(12):e2451245.

PMID: 39359035 PMC: 11631677. DOI: 10.1002/eji.202451245.


Deubiquitination of RIPK2 by OTUB2 augments NOD2 signalling and protective effects in intestinal inflammation.

Du X, Xu J, Mei F, Shen J, Zhou B, Zhu Z Clin Transl Med. 2024; 14(10):e70038.

PMID: 39358938 PMC: 11446981. DOI: 10.1002/ctm2.70038.


YOD1 sustains NOD2-mediated protective signaling in colitis by stabilizing RIPK2.

Shen J, Lou L, Du X, Zhou B, Xu Y, Mei F EMBO Rep. 2024; 25(11):4827-4845.

PMID: 39333628 PMC: 11549337. DOI: 10.1038/s44319-024-00276-6.


References
1.
Chiang Y, Kole H, Brown K, Naramura M, Fukuhara S, Hu R . Cbl-b regulates the CD28 dependence of T-cell activation. Nature. 2000; 403(6766):216-20. DOI: 10.1038/35003235. View

2.
Kufer T, Kremmer E, Banks D, Philpott D . Role for erbin in bacterial activation of Nod2. Infect Immun. 2006; 74(6):3115-24. PMC: 1479233. DOI: 10.1128/IAI.00035-06. View

3.
Ogura Y, Bonen D, Inohara N, Nicolae D, Chen F, Ramos R . A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411(6837):603-6. DOI: 10.1038/35079114. View

4.
Wu C, Conze D, Li T, Srinivasula S, Ashwell J . Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected]. Nat Cell Biol. 2006; 8(4):398-406. DOI: 10.1038/ncb1384. View

5.
Pickart C . Back to the future with ubiquitin. Cell. 2004; 116(2):181-90. DOI: 10.1016/s0092-8674(03)01074-2. View